Please enable JavaScript to continue using this application.

Compare $FHTX vs $SPRB | Chartloom

Compare

$FHTX vs $SPRB

Foghorn Therapeutics Inc · Spruce Biosciences, Inc

FHTX

Foghorn Therapeutics Inc

SPRB

Spruce Biosciences, Inc

Compare $FHTX vs $SPRB

Comparing Foghorn Therapeutics Inc and Spruce Biosciences, Inc

FHTXFoghorn Therapeutics Inc

SPRBSpruce Biosciences, Inc

FHTXFoghorn Therapeutics Inc

Market cap

$117M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

4.04x

Rev growth (TTM)

52.0%

YTD performance

-61.5%

52W performance

-55.6%

FCF yield

-71.8%

SPRBSpruce Biosciences, Inc

Market cap

$121M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-51.4%

52W performance

-72.5%

FCF yield

-35.3%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

FHTX

SPRB

Detailed metrics comparison

FHTX

Foghorn Therapeutics Inc

SPRB

Spruce Biosciences, Inc

Market Cap

FHTX$117M

SPRB$121M

Enterprise Value

FHTX$49M

SPRB$32M

Price

FHTX$2.00

SPRB$44.05

P/E Ratio

FHTXN/A

SPRBN/A

P/S Ratio

FHTX3.20x

SPRB26.75x

EV/Sales

FHTX1.34x

SPRB8.59x

EV/EBITDA

FHTX0.00x

SPRB0.00x

P/B Ratio

FHTX1,199.58x

SPRB1.57x

P/FCF Ratio

FHTXN/A

SPRBN/A

EV/FCF

FHTX-0.59x

SPRB-0.75x

PEG Ratio

FHTXN/A

SPRBN/A

Forward P/E (NTM)

FHTXN/A

SPRBN/A

Forward P/S (NTM)

FHTX4.04x

SPRBN/A

Revenue (TTM)

FHTX$37M

SPRB$0

Revenue Growth (YoY)

FHTX52.0%

SPRBN/A

Forward Rev Growth

FHTX7.3%

SPRB-75.6%

Gross Margin (TTM)

FHTX0.0%

SPRB0.0%

Operating Margin (TTM)

FHTX0.0%

SPRB0.0%

EBITDA Margin (TTM)

FHTX-180.6%

SPRB0.0%

Net Margin (TTM)

FHTX-175.8%

SPRB0.0%

FCF Margin (TTM)

FHTX-229.4%

SPRBN/A

Net Income (TTM)

FHTX$-65M

SPRB$-51M

FCF (TTM)

FHTX$-84M

SPRB$-43M

EPS (TTM)

FHTX-$0.91

SPRB-$21.14

ROE (TTM)

FHTX-30161.0%

SPRB-15540.0%

ROA (TTM)

FHTX-3117.0%

SPRB-10167.0%

ROIC (TTM)

FHTX-30161.0%

SPRB-14349.0%

Cash

FHTX$68M

SPRB$96M

Debt

FHTX$0

SPRB$7M

Net Cash/Debt

FHTX$68M

SPRB$89M

Current Ratio (TTM)

FHTX3.36x

SPRB9.23x

Quick Ratio (TTM)

FHTX3.31x

SPRB8.81x

Debt/Equity (TTM)

FHTX0.00x

SPRB0.08x

Debt/Assets (TTM)

FHTX0.0%

SPRB0.0%

Interest Coverage (TTM)

FHTXN/A

SPRBN/A

Net Debt/EBITDA (TTM)

FHTX0.00x

SPRB0.00x

Beta

FHTX3.13

SPRB3.63

52W Performance

FHTX-55.6%

SPRB-72.5%

YTD Performance

FHTX-61.5%

SPRB-51.4%

% from 52W High

FHTX-73.7%

SPRB-77.9%

% from 52W Low

FHTX11.7%

SPRB9.2%

Asset Turnover (TTM)

FHTX0.18x

SPRB0.07x

FCF Yield (TTM)

FHTX-71.8%

SPRB-35.3%

Earnings Yield (TTM)

FHTX-55.0%

SPRB-42.4%

Dividend Yield (TTM)

FHTXN/A

SPRBN/A

Rule of 40

FHTX-177.4

SPRB0.0

EV/GP/RG

FHTXN/A

SPRBN/A

Ticker research

View FHTX research View SPRB research

Metric	FHTX Foghorn Therapeutics Inc	SPRB Spruce Biosciences, Inc
Market & Valuation
Market Cap	$117M	$121M
Enterprise Value	$49M	$32M
Price	$2.00	$44.05
P/E Ratio	N/A	N/A
P/S Ratio	3.20x	26.75x
EV/Sales	1.34x	8.59x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1,199.58x	1.57x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.59x	-0.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.04x	N/A
Revenue & Growth
Revenue (TTM)	$37M	$0
Revenue Growth (YoY)	52.0%	N/A
Forward Rev Growth	7.3%	-75.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-180.6%	0.0%
Net Margin (TTM)	-175.8%	0.0%
FCF Margin (TTM)	-229.4%	N/A
Net Income (TTM)	$-65M	$-51M
FCF (TTM)	$-84M	$-43M
EPS (TTM)	-$0.91	-$21.14
ROE (TTM)	-30161.0%	-15540.0%
ROA (TTM)	-3117.0%	-10167.0%
ROIC (TTM)	-30161.0%	-14349.0%
Financial Health
Cash	$68M	$96M
Debt	$0	$7M
Net Cash/Debt	$68M	$89M
Current Ratio (TTM)	3.36x	9.23x
Quick Ratio (TTM)	3.31x	8.81x
Debt/Equity (TTM)	0.00x	0.08x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.13	3.63
52W Performance	-55.6%	-72.5%
YTD Performance	-61.5%	-51.4%
% from 52W High	-73.7%	-77.9%
% from 52W Low	11.7%	9.2%
Efficiency & Yields
Asset Turnover (TTM)	0.18x	0.07x
FCF Yield (TTM)	-71.8%	-35.3%
Earnings Yield (TTM)	-55.0%	-42.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-177.4	0.0
EV/GP/RG	N/A	N/A
Ticker research	View FHTX research	View SPRB research

Valuation

P/S Ratio

FHTX

3.20x

SPRB

26.75x

EV/FCF

SPRB

-0.75x

FHTX

-0.59x

Growth & revenue

Revenue Growth TTM

FHTX

52.0%

Forward Revenue Growth

FHTX

7.3%

SPRB

-75.6%

Profitability & performance

Gross Margin

FHTX

0.0%

SPRB

0.0%

ROE

SPRB

-15540.0%

FHTX

-30161.0%

FCF Yield %

SPRB

-35.3%

FHTX

-71.8%

52-Week Performance

FHTX

-55.6%

SPRB

-72.5%

Detailed metrics comparison

FHTX

Foghorn Therapeutics Inc

SPRB

Spruce Biosciences, Inc

Market Cap

FHTX$117M

SPRB$121M

Enterprise Value

FHTX$49M

SPRB$32M

Price

FHTX$2.00

SPRB$44.05

P/E Ratio

FHTXN/A

SPRBN/A

P/S Ratio

FHTX3.20x

SPRB26.75x

EV/Sales

FHTX1.34x

SPRB8.59x

EV/EBITDA

FHTX0.00x

SPRB0.00x

P/B Ratio

FHTX1,199.58x

SPRB1.57x

P/FCF Ratio

FHTXN/A

SPRBN/A

EV/FCF

FHTX-0.59x

SPRB-0.75x

PEG Ratio

FHTXN/A

SPRBN/A

Forward P/E (NTM)

FHTXN/A

SPRBN/A

Forward P/S (NTM)

FHTX4.04x

SPRBN/A

Revenue (TTM)

FHTX$37M

SPRB$0

Revenue Growth (YoY)

FHTX52.0%

SPRBN/A

Forward Rev Growth

FHTX7.3%

SPRB-75.6%

Gross Margin (TTM)

FHTX0.0%

SPRB0.0%

Operating Margin (TTM)

FHTX0.0%

SPRB0.0%

EBITDA Margin (TTM)

FHTX-180.6%

SPRB0.0%

Net Margin (TTM)

FHTX-175.8%

SPRB0.0%

FCF Margin (TTM)

FHTX-229.4%

SPRBN/A

Net Income (TTM)

FHTX$-65M

SPRB$-51M

FCF (TTM)

FHTX$-84M

SPRB$-43M

EPS (TTM)

FHTX-$0.91

SPRB-$21.14

ROE (TTM)

FHTX-30161.0%

SPRB-15540.0%

ROA (TTM)

FHTX-3117.0%

SPRB-10167.0%

ROIC (TTM)

FHTX-30161.0%

SPRB-14349.0%

Cash

FHTX$68M

SPRB$96M

Debt

FHTX$0

SPRB$7M

Net Cash/Debt

FHTX$68M

SPRB$89M

Current Ratio (TTM)

FHTX3.36x

SPRB9.23x

Quick Ratio (TTM)

FHTX3.31x

SPRB8.81x

Debt/Equity (TTM)

FHTX0.00x

SPRB0.08x

Debt/Assets (TTM)

FHTX0.0%

SPRB0.0%

Interest Coverage (TTM)

FHTXN/A

SPRBN/A

Net Debt/EBITDA (TTM)

FHTX0.00x

SPRB0.00x

Beta

FHTX3.13

SPRB3.63

52W Performance

FHTX-55.6%

SPRB-72.5%

YTD Performance

FHTX-61.5%

SPRB-51.4%

% from 52W High

FHTX-73.7%

SPRB-77.9%

% from 52W Low

FHTX11.7%

SPRB9.2%

Asset Turnover (TTM)

FHTX0.18x

SPRB0.07x

FCF Yield (TTM)

FHTX-71.8%

SPRB-35.3%

Earnings Yield (TTM)

FHTX-55.0%

SPRB-42.4%

Dividend Yield (TTM)

FHTXN/A

SPRBN/A

Rule of 40

FHTX-177.4

SPRB0.0

EV/GP/RG

FHTXN/A

SPRBN/A

Ticker research

View FHTX research View SPRB research

Metric	FHTX Foghorn Therapeutics Inc	SPRB Spruce Biosciences, Inc
Market & Valuation
Market Cap	$117M	$121M
Enterprise Value	$49M	$32M
Price	$2.00	$44.05
P/E Ratio	N/A	N/A
P/S Ratio	3.20x	26.75x
EV/Sales	1.34x	8.59x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1,199.58x	1.57x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.59x	-0.75x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	4.04x	N/A
Revenue & Growth
Revenue (TTM)	$37M	$0
Revenue Growth (YoY)	52.0%	N/A
Forward Rev Growth	7.3%	-75.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-180.6%	0.0%
Net Margin (TTM)	-175.8%	0.0%
FCF Margin (TTM)	-229.4%	N/A
Net Income (TTM)	$-65M	$-51M
FCF (TTM)	$-84M	$-43M
EPS (TTM)	-$0.91	-$21.14
ROE (TTM)	-30161.0%	-15540.0%
ROA (TTM)	-3117.0%	-10167.0%
ROIC (TTM)	-30161.0%	-14349.0%
Financial Health
Cash	$68M	$96M
Debt	$0	$7M
Net Cash/Debt	$68M	$89M
Current Ratio (TTM)	3.36x	9.23x
Quick Ratio (TTM)	3.31x	8.81x
Debt/Equity (TTM)	0.00x	0.08x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.13	3.63
52W Performance	-55.6%	-72.5%
YTD Performance	-61.5%	-51.4%
% from 52W High	-73.7%	-77.9%
% from 52W Low	11.7%	9.2%
Efficiency & Yields
Asset Turnover (TTM)	0.18x	0.07x
FCF Yield (TTM)	-71.8%	-35.3%
Earnings Yield (TTM)	-55.0%	-42.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-177.4	0.0
EV/GP/RG	N/A	N/A
Ticker research	View FHTX research	View SPRB research